Ben Aylor
Managing Director & Senior Partner
Washington, DC
Ben Aylor is a core member of Boston Consulting Group’s Health Care and Operations practice areas. He is BCG's global topic leader on network strategy for pharmaceutical manufacturing and has extensive experience with both strategy and operations projects in the pharmaceuticals industry, including biopharma network designs, operations transformations, make/buy analyses, and sourcing strategies.
Ben’s current focus is on helping clients build their capabilities in new areas—such as digital supply chain—and meet the challenges of major change efforts including post-merger integrations and broad transformations. Ben has led both overall corporate PMI programs and the manufacturing aspects of PMIs.
Before joining the firm, Ben worked at Arthur Andersen Business Consulting.
The new administration will fight to advance and protect US economic interests—but America will no longer go it alone.
As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
企業はパンデミックにより露呈した構造的問題に対処するため、グローバル生産・供給ネットワークを再考し、レジリエンスを高める必要があります――たとえ、それがコスト増につながるとしても。
To address flaws exposed by the pandemic, companies should accelerate efforts to revamp their worldwide manufacturing and sourcing networks—even if that means extra cost.
Even when the global economy fully recovers, the international trade landscape will look dramatically different in the years ahead than it did before the pandemic.
Medtech and biopharma companies can rebound from the current crisis and prepare for an uncertain future.
Plans to tax CO2 emissions that are attributed to imports would hike costs for EU trade partners and redefine competitive advantage in many industries.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
Understand the situation in your industry, consider multiple scenarios, and plot out both immediate actions and longer-term steps to lay the foundation for a strong recovery.
Companies are eager to shift more of the production they outsource to trusted strategic partners, but doing that right takes analysis and planning.
